Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial Mahmut.

Slides:

Advertisements

Similar presentations

FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease Mahmut I. Yilmaz, Alper Sonmez, Mutlu Saglam, Halil Yaman, Selim.

Advertisements

ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease K. Caglar, M.I. Yilmaz, A. Sonmez, E. Cakir, A. Kaya, C. Acikel,

Volume 75, Issue 12, Pages (June 2009)

Volume 70, Issue 4, Pages (August 2006)

Renal Function Testing

Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole

Fibroblast Growth Factor 23 and CKD Prognosis

Frederic Rahbari-Oskoui, MD, MS American Journal of Kidney Diseases

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Phosphate Kinetic Models in Hemodialysis: A Systematic Review

Hypertension in the hemodialysis patient and the “lag phenomenon”: insights into pathophysiology and clinical management Uday M Khosla, MD, Richard J.

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Francesca Mallamaci, MD, Giovanni Tripepi, PhD

A Decade After the KDOQI CKD Guidelines

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-

Sevelamer Prescriptions After Reporting of the Dialysis Clinical Outcomes Revisited (DCOR) Trial Findings: An Analysis of 5,495 Patients Receiving Maintenance.

Evaluation of the Potential Living Kidney Donor

Focusing on Health Literacy Might Help Us Cross the Quality Chasm

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

National Kidney Foundation American Journal of Kidney Diseases

Salt and Hypertension American Journal of Kidney Diseases

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial Steven Fishbane, MD, Sofia Agoritsas, MPA, Alessandro Bellucci, MD, Candice Halinski,

Effect of Fish Oil on Vitamin D Absorption

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Hypomagnesemia in a Patient With an Eating Disorder

Hemoglobin Level and Transfusions in Patients on Maintenance Dialysis: Where the Rubber Meets the Road Eduardo Lacson, MD, MPH, Franklin Maddux, MD

Nosratola D. Vaziri, MD American Journal of Kidney Diseases

Navdeep Tangri, MD, FRCPC, Daniel E. Weiner, MD, MS

A Decade After the KDOQI CKD Guidelines: A Historical Perspective

CKD as an Underrecognized Threat to Patient Safety

Hypertension After Kidney Transplant

Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C

Hypertension in the hemodialysis patient and the “lag phenomenon”: insights into pathophysiology and clinical management Uday M Khosla, MD, Richard J.

Polyunsaturated Fatty Acids and Kidney Disease

Elevated Fibroblast Growth Factor 23 in a Patient With Metastatic Prostate Cancer and Hypophosphatemia Casey L. Cotant, MD, Panduranga S. Rao, MD, DNB,

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial Delphine S. Tuot, Charles E.

Salicylate Intoxication as a Cause of Pseudohyperchloremia

Quiz Page April 2008 American Journal of Kidney Diseases

Study Designs in Patient-Oriented Research

Evidence and Outcomes in CKD

Erratum American Journal of Kidney Diseases

The future of renoprotection: Frustration and promises

Long-term Outcomes of Acute Kidney Injury: The Power and Pitfalls of Observational/Population-Based Studies Charuhas V. Thakar, MD American Journal.

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Trial Quality in Nephrology: How Are We Measuring Up?

Multidrug-Resistant Organisms Within the Dialysis Population: A Potentially Preventable Perfect Storm David P. Calfee, MD, MS American Journal of Kidney.

Volume 78, Issue 7, Pages (October 2010)

Making Music American Journal of Kidney Diseases

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 73, Issue 5, Pages (March 2008)

Michael Allon, MD American Journal of Kidney Diseases

Erratum American Journal of Kidney Diseases

Volume 70, Issue 4, Pages (August 2006)

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

Juan Jesús Carrero, PhD American Journal of Kidney Diseases

James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD

Jordi Goldstein-Fuchs, DSc, RD, RN, Denis Fouque, MD, PhD

Dialysis Research and N-of-1 Trials: Made for Each Other?

Quiz Page January 2010 American Journal of Kidney Diseases

Clinical Practice Recommendations For Peritoneal Dialysis Adequacy

A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Adam Whaley-Connell, DO, MSPH

Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Quiz page December 2003 American Journal of Kidney Diseases

Phosphate Balance in Continuous Venovenous Hemofiltration

Presentation transcript:

Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial Mahmut Ilker Yilmaz, MD, Alper Sonmez, MD, Mutlu Saglam, MD, Halil Yaman, MD, Selim Kilic, MD, Tayfun Eyileten, MD, Kayser Caglar, MD, Yusuf Oguz, MD, Abdulgaffar Vural, MD, Mujdat Yenicesu, MD, Francesca Mallamaci, MD, Carmine Zoccali, MD American Journal of Kidney Diseases Volume 59, Issue 2, Pages 177-185 (February 2012) DOI: 10.1053/j.ajkd.2011.11.007 Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Flow chart of patients enrolled in the trial. Abbreviations: ACE, angiotensin-converting enzyme [inhibitor]; ARB, angiotensin receptor blocker; CKD, chronic kidney disease. American Journal of Kidney Diseases 2012 59, 177-185DOI: (10.1053/j.ajkd.2011.11.007) Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Relationships between baseline flow-mediated vasodilatation values with (A) fibroblast growth factor 23 (FGF-23) and (B) serum phosphate (PO4) levels. American Journal of Kidney Diseases 2012 59, 177-185DOI: (10.1053/j.ajkd.2011.11.007) Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

Figure 3 Relationships between changes (delta) in flow-mediated vasodilatation (FMD) and simultaneous changes in fibroblast growth factor 23 (FGF-23) levels in sevelamer- and calcium acetate–treated patients. American Journal of Kidney Diseases 2012 59, 177-185DOI: (10.1053/j.ajkd.2011.11.007) Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions